Edition:
United States

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

12.04USD
20 Feb 2018
Change (% chg)

$0.13 (+1.09%)
Prev Close
$11.91
Open
$11.84
Day's High
$12.19
Day's Low
$11.82
Volume
46,191
Avg. Vol
46,956
52-wk High
$19.50
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22
Thursday, 1 Feb 2018 05:18pm EST 

Feb 1 (Reuters) - Oxford Immunotec Global Plc ::JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING.  Full Article

Oxford Immunotec Announces Preliminary Revenue For Q4
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Oxford Immunotec Global Plc ::FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S.OXFORD IMMUNOTEC ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER AND FULL YEAR 2017.SEES FY 2017 REVENUE $103 MILLION TO $103.5 MILLION.SEES Q4 2017 REVENUE $24.9 MILLION TO $25.4 MILLION.Q4 REVENUE VIEW $26.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
Friday, 15 Dec 2017 04:04pm EST 

Dec 15 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL - UNDER TERMS OF AGREEMENT, ALL PENDING CLAIMS BETWEEN OXFORD, QIAGEN AND CO-DEFENDANTS HAVE BEEN RESOLVED.OXFORD IMMUNOTEC GLOBAL - CO GRANTED QIAGEN ROYALTY-FREE, NON-EXCLUSIVE LICENSE THAT EXTENDS TO ALL CURRENT AND FUTURE CUSTOMERS OF QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - PATENT INFRINGEMENT IS IN RELATION TO QIAGEN'S QUANTIFERON-TB GOLD AND QUANTIFERON-TB GOLD PLUS PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - OXFORD GRANTED QIAGEN A ROYALTY-FREE, NON-EXCLUSIVE LICENSE IN EXCHANGE FOR A ONE-TIME, LUMP-SUM PAYMENT OF $27.5 MILLION.  Full Article

Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​
Tuesday, 21 Nov 2017 05:06pm EST 

Nov 21 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​.Oxford Immunotec Global says ‍second amendment extends term of agreement until December 31, 2023 & establishes pricing - SEC Filing​.  Full Article

Oxford Immunotec Global Q3 loss per share $0.70
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec reports third quarter 2017 financial results.Q3 loss per share $0.70.Sees Q4 2017 revenue $25.4 million to $26.4 million.Q3 revenue $30.4 million versus I/B/E/S view $30 million.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $103.5 million to $104.5 million.FY2017 revenue view $104.6 million -- Thomson Reuters I/B/E/S.  Full Article

Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares
Tuesday, 15 Aug 2017 09:00am EDT 

Aug 15 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares.Oxford Immunotec Global Plc - ‍pricing of its previously announced underwritten public offering of 2.5 million ordinary shares​.Oxford Immunotec Global Plc - ‍aggregate gross proceeds from offering to Oxford Immunotec will be $40.125 million​.  Full Article

Oxford Immunotec Global announces agreement to sell 2.5 mln ordinary shares
Monday, 14 Aug 2017 04:20pm EDT 

Aug 14 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc announces agreement to sell 2,500,000 ordinary shares.Oxford Immunotec Global Plc - ‍ agreement to sell 2.5 million ordinary shares to Btig, Llc as underwriter in an underwritten public offering​.Oxford Immunotec Global Plc - ‍oxford immunotec intends to use net proceeds from offering for working capital and general corporate purposes​.  Full Article

Oxford Immunotec Q2 loss per share $0.74
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Oxford Immunotec Global Plc :Oxford immunotec reports second quarter 2017 financial results.Q2 loss per share $0.74.Sees q3 2017 revenue $29.5 million to $30.5 million.Q2 revenue $26.1 million versus i/b/e/s view $25 million.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue $103 million to $106 million.  Full Article

Oxford Immunotec Global says unit entered into amendment to marketing authorization holder agreement with Riken Genesis
Friday, 28 Jul 2017 04:52pm EDT 

July 28 (Reuters) - Oxford Immunotec Global Plc ::Oxford Immunotec Global Plc - on july 24, unit of co entered into amendment to marketing authorization holder agreement with Riken Genesis Co., Ltd.Oxford Immunotec Global Plc - amendment amends marketing authorization holder agreement between parties dated july 29, 2011, as amended april 1, 2016.Oxford Immunotec Global Plc - amendment modifies termination provision of agreement and memorializes monthly retainer applicable to services.  Full Article

Oxford Immunotec posts Q1 loss per share of $0.36
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - Oxford Immunotec Global Plc :Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $-1.03 -- Thomson Reuters I/B/E/S.Reports first quarter 2017 financial results.Q1 loss per share $0.36.Sees q2 2017 revenue $24.9 million to $25.7 million.Q1 revenue $21.5 million versus i/b/e/s view $21.2 million.Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue $102 million to $105 million.Expect revenue to increase 21% to 24% for year using constant exchange rates.  Full Article

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage: